🇺🇸 FDA
Patent

US 11702415

Crystalline hydrate of a JAK inhibitor compound

granted A61KA61K9/0053A61P

Quick answer

US patent 11702415 (Crystalline hydrate of a JAK inhibitor compound) held by Theravance Biopharma R&D IP, LLC expires Mon Jul 13 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Theravance Biopharma R&D IP, LLC
Grant date
Tue Jul 18 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 13 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
22
CPC classes
A61K, A61K9/0053, A61P, A61P11/00, A61P11/06